Pay in 4 interest-free payments of $29.75 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Navitoclax-piperazine (ABT-263-piperazine) is a B-cell lymphoma extra large (BCL-XL) inhibitor
which has been previously shown for other protein methyltransferase inhibitors binding at the substrate pocket
InChi: InChI=1S/C24H21N3O3/c28-22(18-11-5-2-6-12-18)26-24-25-20-16-19(23(29)30)13-14-21(20)27(24)15-7-10-17-8-3-1-4-9-17/h1-6
which is an anticancer drug candidate currently in clinical trials
β-Interleukin II (44-56) Size:Contact [email protected] for quotation Navitoclax-piperazine (ABT-263-piperazine) is a B-cellInterleukin II (44 56), (C68H113N19O19) is a peptide with the sequence NH2 ILE LEU ASN GLY ILE ASN ASN TYR LYS ASN PRO LYS LEU COOH, MW= 1500. 7. Interleukin 2 (IL 2) belongs to the interleukin family, a type of cytokine signaling molecule in the immune system, and it is a protein that regulates the activities of the white blood cells (leukocytes, often lymphocytes) responsible for immunity. IL 2, a soluble hormone like mediator of the immune system,